LYFCX Holdings — AlphaCentric Life Sciences and Healthcare Fund
All 62 reported holdings of AlphaCentric Life Sciences and Healthcare Fund (LYFCX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Gilead Sciences, Inc. | 5.53% | $2.58M |
| Vertex Pharmaceuticals, Inc. | 5.33% | $2.48M |
| Astrazeneca PLC | 4.63% | $2.16M |
| First American Funds, Inc. | 4.26% | $1.99M |
| Roivant Sciences Ltd. | 3.67% | $1.71M |
| Argenx SE | 3.59% | $1.68M |
| Neurocrine Biosciences, Inc. | 3.51% | $1.64M |
| Incyte Corp. | 3.51% | $1.64M |
| Axsome Therapeutics, Inc. | 3.43% | $1.60M |
| Apogee Therapeutics, Inc. | 3.28% | $1.53M |
| Ionis Pharmaceuticals, Inc. | 2.62% | $1.22M |
| Ascendis Pharma A/s | 2.62% | $1.22M |
| Insmed, Inc. | 2.60% | $1.21M |
| Protagonist Therapeutics, Inc. | 2.41% | $1.12M |
| Personalis, Inc. | 2.27% | $1.06M |
| Rhythm Pharmaceuticals, Inc. | 2.25% | $1.05M |
| Abbvie, Inc. | 1.95% | $909.18K |
| Jazz Pharmaceuticals PLC | 1.87% | $870.62K |
| Amgen, Inc. | 1.83% | $855.33K |
| Biogen, Inc. | 1.80% | $840.69K |
| Catalyst Pharmaceuticals, Inc. | 1.59% | $742.44K |
| Halozyme Therapeutics, Inc. | 1.58% | $737.77K |
| Meiragtx Holdings PLC | 1.58% | $735.88K |
| Krystal Biotech, Inc. | 1.55% | $722.90K |
| Nuvalent, Inc. | 1.47% | $686.41K |
| Abivax SA | 1.47% | $685.09K |
| Edgewise Therapeutics, Inc. | 1.38% | $643.58K |
| Nurix Therapeutics, Inc. | 1.34% | $627.00K |
| Sanofi SA | 1.33% | $622.41K |
| Oruka Therapeutics, Inc. | 1.33% | $621.56K |
| Kymera Therapeutics, Inc. | 1.32% | $617.50K |
| Spyre Therapeutics, Inc. | 1.27% | $592.16K |
| Biontech SE | 1.25% | $583.05K |
| Agios Pharmaceuticals, Inc. | 1.13% | $525.96K |
| Newamsterdam Pharma Company NV | 1.08% | $503.88K |
| Cytokinetics, Inc. | 1.04% | $485.33K |
| Celldex Therapeutics, Inc. | 1.02% | $475.69K |
| Trevi Therapeutics, Inc. | 0.97% | $453.51K |
| Alnylam Pharmaceuticals, Inc. | 0.90% | $418.43K |
| Veracyte, Inc. | 0.87% | $408.06K |
| Candel Therapeutics, Inc. | 0.81% | $377.83K |
| Natera, Inc. | 0.81% | $377.32K |
| Rezolute, Inc. | 0.81% | $375.73K |
| Cullinan Therapeutics, Inc. | 0.80% | $371.96K |
| Crinetics Pharmaceuticals, Inc. | 0.79% | $369.19K |
| Xeris Biopharma Holdings, Inc. | 0.79% | $368.67K |
| Design Therapeutics, Inc. | 0.67% | $311.64K |
| Monte Rosa Therapeutics, Inc. | 0.66% | $306.01K |
| Disc Medicine, Inc. | 0.63% | $294.75K |
| Rapport Therapeutics, Inc. | 0.58% | $272.15K |
| Arvinas, Inc. | 0.55% | $254.47K |
| Icon PLC | 0.52% | $241.46K |
| Tectonic Therapeutic, Inc. | 0.51% | $238.84K |
| Sionna Therapeutics, Inc. | 0.46% | $213.92K |
| Wave Life Sciences Ltd. | 0.44% | $207.24K |
| Intellia Therapeutics, Inc. | 0.42% | $197.49K |
| Atrium Therapeutics, Inc. | 0.39% | $181.28K |
| Iqvia Holdings, Inc. | 0.35% | $161.15K |
| Annexon, Inc. | 0.30% | $142.02K |
| Adma Biologics, Inc. | 0.18% | $84.90K |
| Aldeyra Therapeutics, Inc. | 0.17% | $80.21K |
| Alkermes PLC | 0.00% | $0 |
LYFCX overview: performance, fees, allocation and SEC filings